SCHEMBL5397691

SCHEMBL5397691

O=S(=O)(Nc1nnc(C(F)(F)F)s1)c1ccc(Br)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.75
▸ KMT2A Q03164 7/20 0.75
▸ CA1 P00915 3/20 0.60
▸ CA2 P00918 3/20 0.60
▸ CA12 O43570 1/20 0.60
▸ CA9 Q16790 1/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ CA4 P22748 1/20 0.55
▸ CA5A P35218 1/20 0.55
▸ CA5B Q9Y2D0 1/20 0.55
▸ ALDH1A1 P00352 6/20 0.53
▸ HPGD P15428 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ PKM P14618 1/20 0.50
▸ AKT1 P31749 1/20 0.47
▸ LMNA P02545 3/20 0.47
▸ HTT P42858 3/20 0.47
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396309 0.87 KMT2A (0.77) MEN1KMT2ACA1CA2SMN1; SMN2
SCHEMBL5404442 0.86 ALDH1A1 (0.71) MEN1KMT2ACA1CA2CA12
SCHEMBL5391647 0.86 MEN1 (0.75) MEN1KMT2ACA1CA2CA4
SCHEMBL5391636 0.86 MEN1 (1.00) MEN1KMT2ACA1CA2SMN1; SMN2
SCHEMBL5394860 0.85 MEN1 (0.74) MEN1KMT2ACA1CA2CA12
SCHEMBL5389518 0.80 MEN1 (0.74) MEN1KMT2ACA1CA2CA12
Hydrochloric Acid SCHEMBL3789519 0.79 MEN1 (0.65) MEN1KMT2ACA1CA2CA12
SCHEMBL5385416 0.77 KMT2A (0.62) MEN1KMT2ACA1CA2CA4
SCHEMBL15212800 0.76 ALPL (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1HPGD
SCHEMBL9795893 0.75 CA1 (1.00) CA1CA2CA12CA9CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 — — US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 — — EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 — — US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 — — WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 — — US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 — — US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 — — EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 — — US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MEN1 942/4885KMT2A 3325/4885CA1 1267/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 MEN1 974/4885KMT2A 3281/4885CA1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback